VXA-CoV2-1 oral pill

May 07, 2026 — Vaxart, Inc. (OTCQX: VXRT) provided a business update and reported first-quarter 2026 financial results, highlighting progress in its BARDA-collaborative Phase 2b COVID-19 trial comparing Vaxart’s oral pill vaccine with a commercially available mRNA vaccine. The trial is fully enrolled with ~5,400 participants across a 400-person sentinel cohort and a ~5,000-participant main KP.2 cohort. Vaxart expects topline 12‑month safety and immunogenicity data from the sentinel cohort in Q2 2026; the sentinel cohort was not powered for statistically significant comparisons. Primary efficacy and safety data from the main cohort are anticipated in early 2027. Vaxart reported cumulative BARDA contract cash payments of $218.9 million as of March 31, 2026.

Financially, cash, cash equivalents, and short-term investments were $61.0 million (runway into Q2 2027). Q1 2026 revenue was $39.2 million (vs. $20.9 million in Q1 2025), R&D expense $29.4 million, G&A $4.6 million, and net income $5.2 million ($0.02/share) versus a net loss of $15.6 million ($0.07/share) a year prior. Vaxart also signed a $25 million equity line with Lincoln Park Capital, added Dr. James B. Breitmeyer to its board, and relocated headquarters to reduce overhead.